Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - REGENERX BIOPHARMACEUTICALS INC | c14252exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2011
REGENERX BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-15070 | 52-1253406 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
15245 Shady Grove Road, Suite 470, Rockville, MD |
20850 |
|
(Address of principal executive offices) | (Zip Code) |
Registrants
telephone number, including area code: (301) 208-9191
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On March 14, 2011, RegeneRx Biopharmaceuticals, Inc. (the Company) received notice from the U.S.
Food and Drug Administration that the Companys Phase 2 clinical trial of its product candidate
RGN-352, for the treatment of acute myocardial infarction, had been placed on clinical hold due to
compliance issues at the Companys contract manufacturer. On March 16, 2011, the Company issued a
press release with respect to this matter, the full text of which is attached as Exhibit 99.1
hereto and is incorporated by reference in this report.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. | Description | |
99.1
|
Press Release dated March 16, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENERX BIOPHARMACEUTICALS, INC. | |||||
Date: March 16, 2011 | |||||
By: | /s/ C. Neil Lyons | ||||
Name: | C. Neil Lyons | ||||
Title: | Chief Financial Officer |
EXHIBIT INDEX
Exhibit | ||
No. | Description | |
99.1
|
Press Release dated March 16, 2011 |